{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-044375","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.975753+00:00","generated_at":"2026-05-24T06:12:11.102701+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tenax Therapeutics reports FY2024 net loss of $17.6M; $94.9M cash; raised $125M for TNX-103 Phase 3 trials","bullets":["Net loss for FY2024 was $17.6M vs $7.7M in 2023; Q4 net loss $6.3M vs $3.2M.","Cash and cash equivalents $94.9M as of Dec 31, 2024; plus $25M March 2025 private placement, funding through 2027.","Phase 3 LEVEL study enrollment expanded to 230 patients; topline data expected mid-2026.","Second Phase 3 study LEVEL-2 expected to initiate in 2025.","R&D expenses $12.7M in 2024 vs $3.2M in 2023, driven by Phase 3 LEVEL study."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-044375","json":"https://secwatch.observer/filing/0000950170-25-044375.json","markdown":"https://secwatch.observer/filing/0000950170-25-044375.md","text":"https://secwatch.observer/filing/0000950170-25-044375.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000095017025044375/0000950170-25-044375-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000095017025044375/form-8-k-ye-2024v2.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:12:11.102701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}